Recently, Merge Healthcare Inc. (MRGE) and Microdata Tecnologia of Brazil entered into a distribution agreement whereby the latter will have exclusive access to the Portuguese version of Merge’s eFilm Workstation. Microdata Tecnologia will use eFilm Workstation to replace the viewing component of its current Picture Archiving and Communication System (PACS), designed to enhance the medical imaging solution.
eFilm Workstation is a diagnostic workstation that is the most downloaded software used for viewing medical images. The company wants to exploit the benefits from this Portuguese-language version of eFilm Workstation for expanding its reach in the imaging market, where digital imaging is quickly coming up.
Microdata Tecnologia manufactures PACS and Medical Imaging Technology and possesses a competitive position in the Brazilian market with a 20% market share. The company’s partnership with Merge would lead to the expansion of its PACS business and help maintain its competitive position in Brazil.
Brazil is one of the fastest-growing emerging markets in the world. Based on the expansion as well as adoption of new technologies, the PACS market in Brazil is expected to grow at a CAGR of 32.4% from fiscal 2005 through fiscal 2015.
Merge is a health care software and services company focused on integrating radiology workflow to improve productivity, profitability and patient care by fusing business and clinical workflow. It provides its eTrials software and services to pharmaceutical, biotech, medical device and Contract Research Organizations to facilitate data capture, logistics, patient interaction and clinical trial management. Merge’s eFilm Workstation also includes other language versions such as Spanish, Japanese, Russian and Polish.
Merge has ample growth potential in the diagnostic imaging workflow applications market. In today’s digital world, film has become almost obsolete. We believe this partnership would strengthen Merge’s foothold in the upcoming imaging market.
Read the full analyst report on “MRGE”
Zacks Investment Research
